Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (MPS II) and TransportVehicle™ Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 WORLDSymposium™
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), today announced upcoming oral (platform) and poster presentations at the 21st Annual WORLD Symposium ™, which will be held February 3-7, 2025, in San Diego, California. The oral presentation includes clinical results related to its Hunter syndrome (MPS II) investigational therapeutic, tividenofusp alfa (DNL310). Tividenofusp alfa is enabled by the Denali TransportVehicle™ platform, which is designed to effectively deliver enzyme, oligonucleotide, or antibody therapeutics to all tissues in the body, including the brain by crossing the blood-brain barrier.
The presentation schedule at WORLD Symposium ™ 2025 is as follows:
Title: Interim Analysis of Efficacy and Safety of Weekly Intravenous Tividenofusp Alfa in Mucopolysaccharidosis Type II (MPS II) – Platform Presentation
Session: Clinical Applications Platform Presentations
Date: Thursday, February 6, 2025
Session Time: 8:30 AM Pacific Time
Title: Unmet Needs in the Treatment and Care of Somatic Manifestations in People with Mucopolysaccharidosis Type II (Hunter Syndrome): A Targeted Literature Review – Poster #44
Session: Translational Research – Poster Session II
Date: Thursday, February 6, 2025
Session Time: 3:30 – 5:30 PM Pacific Time
Title: Age-Dependent Reference Intervals for Cerebrospinal Fluid (CSF) and Urine Heparan Sulfate (HS) and Dermatan Sulfate (DS) and CSF Gangliosides – Poster #132
Session: Clinical Applications – Poster Session III
Date: Thursday, February 6, 2025
Session Time: 3:30 – 5:30 PM Pacific Time
Denali is also sponsoring the following satellite symposium event at WORLD Symposium ™ 2025:
Title: Voices in Unison – Insights into the Unmet Needs in MPS II from Patient Community and Physician Perspectives (Chair: Barbara K. Burton, M.D.; Speakers: Joseph Muenzer, M.D., Ph.D. and Kristin McKay, President and Executive Director of Project Alive)
Date: Wednesday, February 5, 2025
Time: 6:45 – 7:45 AM Pacific Time
About Denali Therapeutics
Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases. Denali pursues new treatments by rigorously assessing genetically validated targets, engineering delivery across the blood-brain barrier and guiding development through biomarkers that demonstrate target and pathway engagement. Denali is based in South San Francisco. For additional information, please visit www.denalitherapeutics.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements by Denali Therapeutics Inc. ('Denali' or the 'Company') regarding Denali's planned presentations and events at the 2025 WORLD Symposium ™ and expectations related to Denali's TransportVehicle™ (TV) platform. Actual results are subject to risks and uncertainties and may differ materially from those indicated by these forward-looking statements as a result of these risks and uncertainties, including but not limited to: Denali's dependence on successful development of its BBB platform technology and TV-enabled product candidates; Denali's ability to initiate and enroll patients in its current and future clinical trials; Denali's ability to conduct or complete clinical trials on expected timelines; Denali's reliance on third parties for the manufacture and supply of its product candidates for clinical trials; the potential for clinical trial results to differ from preclinical, early clinical, preliminary or expected results; the risk of significant adverse events, toxicities, or other undesirable side effects; the risk that results from early clinical biomarker studies will not translate to clinical benefit in late clinical studies; the risk that product candidates may not receive regulatory approval necessary to be commercialized; developments relating to Denali's competitors and its industry, including competing product candidates and therapies; Denali's ability to obtain, maintain, or protect intellectual property rights; and other risks and uncertainties. In light of these risks, uncertainties, and assumptions, the forward-looking statements in this press release are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Accordingly, you should not rely upon forward-looking statements as predictions of future events. Denali's product candidates are investigational, and their safety and efficacy profiles have not yet been established. No Denali product candidates have been approved by any health authority for any use. Information regarding additional risks and uncertainties may be found in Denali's Annual and Quarterly Reports filed on Forms 10-K and 10-Q filed with the Securities and Exchange Commission (SEC) on February 28, 2024, and November 6, 2024, respectively, and Denali's future reports to be filed with the SEC. Denali does not undertake any obligation to update or revise any forward-looking statements, to conform these statements to actual results or to make changes in Denali's expectations, except as required by law.
Laura Hansen, Ph.D.
(650) 452-2747
Media Contact
Rich Allan
FGS Global
(503) 851-0807
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Musk apology to Trump could reopen path for renewed alliance says Dan Ives
-- Wedbush analyst Dan Ives said in a note Wednesday that Elon Musk's recent apology to President Donald Trump could reopen the path for a renewed alliance, which he views as a "smart move with [the] Robotaxi launch on deck." Musk posted on X, "I regret some of my posts about President Trump last week, They went too far." The Wedbush analyst believes this marks an "important step" in mending fences between the two. Ives feels the apology is crucial because "Musk needs Trump and Trump needs Musk." The firm has observed that the "former BFFs turn against each other has been an overhang on shares of Tesla (NASDAQ:TSLA)," as investors feared a "Trump in revenge mode will make it more difficult for an autonomous future with Tesla front and center." While not expecting a return to their "Mar-a-Lago connected at the hip days," Wedbush anticipates they will "slowly mend the fences" as Trump needs Musk to stay close to the Republican party, and Musk needs Trump for various reasons, including a "green light on a federal framework for autonomous." The timing of the reconciliation is considered notable as Tesla is set to launch its highly anticipated Robotaxi in Austin on June 22. Wedbush sees this as a "major endeavor for Musk and Tesla" and believes the "Trump feud is not getting in the way of this." The core focus for investors, according to Ives, is the "AI Revolution is now coming to Tesla," which will position Tesla as "one of the best pure plays on AI over the next decade" alongside companies like Nvidia (NASDAQ:NVDA) and Microsoft (NASDAQ:MSFT). Wedbush estimates the "AI and autonomous opportunity is worth at least $1 trillion alone for Tesla" and fully expects that "under a Trump White House, these key initiatives will get fast-tracked." They believe "Tesla could reach a $2 trillion market cap by the end of 2026 in a bull case scenario," as the "march to a $2 trillion valuation for TSLA has now begun." Related articles Musk apology to Trump could reopen path for renewed alliance says Dan Ives Ouster shares surge on Pentagon approval for lidar sensor Tesla gains as Musk says he regrets some Trump-related posts Errore nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati
Yahoo
8 minutes ago
- Yahoo
CENT Q1 Earnings Call: Margin Expansion and Cost Discipline Offset Revenue Decline
Pet company Central Garden & Pet (NASDAQ:CENT) missed Wall Street's revenue expectations in Q1 CY2025, with sales falling 7.4% year on year to $833.5 million. Its non-GAAP profit of $1.04 per share was 11.6% above analysts' consensus estimates. Is now the time to buy CENT? Find out in our full research report (it's free). Revenue: $833.5 million vs analyst estimates of $878.8 million (7.4% year-on-year decline, 5.1% miss) Adjusted EPS: $1.04 vs analyst estimates of $0.93 (11.6% beat) Adjusted EBITDA: $119.3 million vs analyst estimates of $114.5 million (14.3% margin, 4.2% beat) Management reiterated its full-year Adjusted EPS guidance of $2.20 at the midpoint Operating Margin: 11.2%, in line with the same quarter last year Market Capitalization: $2.08 billion Central Garden & Pet's latest quarterly results were shaped by shifting seasonal dynamics and ongoing efforts to optimize the business portfolio. Leadership attributed softer sales to the earlier timing of customer orders and promotional events, which pulled demand into the prior quarter, as well as unfavorable weather that delayed the start of the garden season. CEO Niko Lahanas explained, 'the earlier timing of preseason orders and promotional events shifted sales forward into the first quarter, leading to softer sales during the second quarter.' Despite these headwinds, management highlighted the strong performance of the Wild Bird segment and double-digit e-commerce growth as bright spots. Strategic SKU rationalization and cost discipline contributed to margin improvements, and the company continued to streamline operations, including winding down its UK presence in favor of a direct export model. Looking ahead, Central Garden & Pet's outlook reflects both caution and targeted investment in areas with high potential. Management reaffirmed its full-year non-GAAP EPS guidance despite acknowledging increased macroeconomic uncertainty due to tariffs and ongoing geopolitical tensions. Lahanas noted, 'recent tariff actions and related geopolitical tensions have significantly increased macroeconomic uncertainty and weighed on consumer confidence.' The company expects heightened inflationary pressures, particularly in the Pet segment, and is preparing for a more promotional retail environment. Leadership plans to prioritize cost management while investing in e-commerce, digital technology, and further productivity initiatives, emphasizing the importance of agility as weather patterns and consumer behavior remain unpredictable. Management tied the quarter's performance to operational streamlining, portfolio simplification, and targeted investments in logistics and e-commerce, which helped offset external pressures like weather and shifting consumer demand. SKU Rationalization Efforts: Central Garden & Pet accelerated the exit of lower-margin and underperforming product lines, especially in the Pet segment's durable goods, which management cited as a key factor in supporting margins and profitability amid softer demand. Wild Bird Segment Outperformance: The Wild Bird business benefited from prolonged cold weather, driving record sales and mitigating some of the seasonal softness seen in traditional garden categories. This segment also contributed to share gains in both online and brick-and-mortar channels. E-Commerce and Digital Expansion: E-commerce sales saw continued double-digit growth, with enhanced digital capabilities, new product launches, and optimized retail media fueling higher engagement and improved conversion rates across Pet and Garden categories. Distribution and Logistics Upgrades: The company opened new distribution centers and consolidated older ones, introducing direct-to-consumer capabilities and centralizing operations in key categories to drive efficiency and support future growth, particularly in fast-growing segments such as dog and cat products. Cost and Simplicity Program Progress: Continued execution of the Cost and Simplicity program yielded tangible benefits, including cost savings, improved operational flow, and enhanced employee safety. Management expects these initiatives to position the company for additional margin expansion and organic growth. Central Garden & Pet's outlook is shaped by ongoing tariff risks, a more value-focused consumer, and the company's continued investment in digital and operational efficiency. Tariff and Inflation Pressures: Management expects recent tariff actions and geopolitical tensions to increase inflationary pressures in the second half of the year, particularly affecting input costs for the Pet segment. Plans are underway to mitigate these through supply chain adjustments, vendor negotiations, and selective pricing actions, though many changes will not impact results until late this year or next. Promotional Environment and Consumer Behavior: The company anticipates consumers will become more cautious and value-oriented, prompting a more promotional retail landscape and a potential shift toward private label and value products. Management is focused on maintaining competitiveness and margin discipline as these trends evolve. Strategic Investments in E-Commerce and Efficiency: Central Garden & Pet will continue prioritizing investments in e-commerce, technology, and logistics to support organic growth and enhance productivity. The Cost and Simplicity program remains central to operational improvements and potential future margin expansion, even as the company remains watchful for M&A opportunities that align with core categories. In the coming quarters, the StockStory team will monitor (1) the pace and effectiveness of tariff mitigation strategies and supply chain adjustments, (2) trends in consumer trade-down to value and private label products, and (3) the ramp-up in e-commerce and logistics capabilities. We will also assess how ongoing weather variability and promotional intensity affect both the Garden and Pet segments. Central Garden & Pet currently trades at a forward P/E ratio of 16×. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it's free). Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today. Sign in to access your portfolio
Yahoo
8 minutes ago
- Yahoo
2 Cash-Producing Stocks to Research Further and 1 to Avoid
While strong cash flow is a key indicator of stability, it doesn't always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning. Not all companies are created equal, and StockStory is here to surface the ones with real upside. That said, here are two cash-producing companies that leverage their financial strength to beat the competition and one that may struggle to keep up. Trailing 12-Month Free Cash Flow Margin: 37.1% Founded in 2007 as DiscoveryOrg and renamed after a merger in 2019, ZoomInfo (NASDAQ:ZI) is a software as a service product that provides sales departments with access to a database of prospective clients. Why Do We Avoid ZI? Flat billings over the last year suggest it may need to improve its products, pricing, or go-to-market strategy to reinvigorate demand Complex implementation process for enterprise clients means customers take longer to ramp up, as seen in its extended payback periods Day-to-day expenses have swelled relative to revenue over the last year as its operating margin fell by 10.3 percentage points ZoomInfo's stock price of $10.28 implies a valuation ratio of 2.9x forward price-to-sales. Dive into our free research report to see why there are better opportunities than ZI. Trailing 12-Month Free Cash Flow Margin: 10.6% Started by Oleg Shchegolev while still in university, Semrush (NYSE:SEMR) is a software-as-a-service platform that helps companies optimize their search engine and content marketing efforts. Why Are We Positive On SEMR? Average billings growth of 24.8% over the last year enhances its liquidity and shows there is steady demand for its products Sales outlook for the upcoming 12 months implies the business will stay on its desirable three-year growth trajectory Software is difficult to replicate at scale and results in a stellar gross margin of 82.1% At $10.19 per share, Semrush trades at 3.3x forward price-to-sales. Is now a good time to buy? Find out in our full research report, it's free. Trailing 12-Month Free Cash Flow Margin: 2.5% With an emphasis on ethically produced products, Vital Farms (NASDAQ:VITL) specializes in pasture-raised eggs and butter. Why Is VITL a Top Pick? Products are flying off the shelves as its unit sales averaged 17.8% growth over the past two years Expected revenue growth of 26.6% for the next year suggests its market share will rise Earnings per share grew by 161% annually over the last three years and trumped its peers Vital Farms is trading at $33 per share, or 23.8x forward P/E. Is now the right time to buy? See for yourself in our in-depth research report, it's free. The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today for free. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
